RARE — Ultragenyx Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $1.50bn
- $2.35bn
- $673.00m
Brief: Ultragenyx reports inducement grant under Nasdaq listing rule
Ultragenyx Pharmaceutical Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Ultragenyx Q1 EPS USD -1.57 Vs. IBES Estimate USD -1.61
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.61 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ultragenyx Pharma, Winnebago, Par Pacific
Ultragenyx Pharma up after JPMorgan PT raise
U.S. RESEARCH ROUNDUP- Advanced Micro Devices, Carmax, Lockheed Martin
Brief: Ultragenyx reports inducement grant under Nasdaq listing rule 5635(C)(4)
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-General Mills, Meta Platforms, Domino's Pizza
Ultragenyx Pharma rises as FDA accepts genetic disorder therapy for review
Ultragenyx Pharmaceutical Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Ultragenyx Q4 EPS USD -1.39 Vs. IBES Estimate USD -1.29
U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth
U.S. RESEARCH ROUNDUP- Constellation Brands, Merck, WD-40
Brief: Ultragenyx Pharmaceutical Inc Says 2025 Revenue Guidance $640 Mln-$670 Mln
Brief: Ultragenyx Pharma Says EC Expands Evkeeza Approval For HoFH To Children As Young As 6 Months
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Ultragenyx Announces First Patient Dosed In Pivotal Phase 3 Aspire Study Evaluating Gtx-102 In Angelman Syndrome